Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study
I'm PortAI, I can summarize articles.
Quoin Pharmaceuticals Ltd is conducting a clinical study on QRX003 lotion for treating Netherton syndrome, a genetic skin disorder. The study evaluates the lotion's effectiveness and safety over 12 weeks, focusing on symptom improvement. It began on April 7, 2025, and is currently recruiting participants. Positive results could enhance Quoin's market position and influence its stock performance, given the niche market for Netherton syndrome treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments